Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Several possible studies

Story checked

Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD) | Novartis (opens in a new tab)

novartis.com · 2026-09-04

Short answerEvidenceSource

Short answer

Several possible studies

No clear answer.

More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1

The story

Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD) | Novartis

novartis.com · 2026-09-04

The story’s checkable claims.

Read the original story (opens in a new tab)
2

NewsLink checks it

Several studies could be the source of this story.

More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.

Open claim evidence
3

Search result

Several studies could fit.

More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.

Source paper

Source layer

The 7 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Related research

Research nearby

The papers it could be

Nearby papers when the source is unclear.

and 45 more considered

Then inspect each claim

Evidence layer

Claim by claim

What the story asserts. With no source study, there is nothing to check these against.

Claim 1 of 4Not checkedNovartis announced that the phase III Lp(a)HORIZON trial of pelacarsen did not meet its primary endpoint of reducing cardiovascular events compared with placebo.View evidenceHide evidence

As statedprimary endpoint not met

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 2 of 4Not checkedThe primary endpoint was a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization.View evidenceHide evidence

As stated4-point major adverse cardiovascular events composite

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 3 of 4Not checkedLower lipoprotein(a), or Lp(a), levels were achieved with pelacarsen in the study population, which was receiving guideline-directed lipid-lowering and antihypertensive therapy.View evidenceHide evidence

As statedlower Lp(a) levels

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 4 of 4Not checkedNovartis said the findings provide important new evidence on the relationship between Lp(a) lowering and cardiovascular outcomes.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Finally, the search trail

Method layer

No single source study was found.

NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.

Nearby research

No exact source, but these papers are close.

PubMed, Crossref, Europe PMC · 46 candidate papers

And 41 more candidates considered.